PHF8

Histone lysine demethylase PHF8 · Q9UPP1 · PHF8 on Sugi Atlas →

27,079 patent compounds predicted against PHF8, 13,267 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL50347	1.00	8/20
Succinylacetone (SCHEMBL503918)	1.00	7/20
Levulinic Acid (SCHEMBL113572)	0.60	7/20
Levulinic Acid (SCHEMBL377114)	0.55	7/20
Succinic Acid (SCHEMBL173955)	0.52	7/20
Succinic Acid (SCHEMBL209622)	0.48	7/20
SCHEMBL318778	0.42	7/20
SCHEMBL318779	0.42	7/20
SCHEMBL218098	0.65	6/20
Succinic Acid (SCHEMBL35204)	0.58	6/20
SCHEMBL94233	0.50	6/20
SCHEMBL223005	0.50	6/20
SCHEMBL584428	0.80	5/20
Trifluoroacetic Acid (SCHEMBL504173)	0.73	5/20
SCHEMBL322794	0.64	5/20
Levulinic Acid (SCHEMBL357249)	0.52	5/20
SCHEMBL10214	0.50	5/20
SCHEMBL123830	0.46	5/20
SCHEMBL163128	0.43	5/20
SCHEMBL265501	0.43	5/20

Clinical trials — most relevant to PHF8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Safety and Pharmacokinetic Profile of CKD-581	PHASE1	COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid	EARLY_PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Mechanisms of Immune Deficiency	nan	UNKNOWN
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients	nan	COMPLETED
Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins	nan	COMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19	nan	COMPLETED
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Patients With RETT Syndrome	nan	UNKNOWN
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PHF8 binder may also engage these)

Protein	Name	Similarity
Q80TJ7	—	1.000	Q80TJ7 →
P0CH95	—	1.000	P0CH95 →
Q5RHD1	—	0.994	Q5RHD1 →
PHF2	Lysine-specific demethylase PHF2	0.992	landscape →
Q62315	—	0.990	Q62315 →
Q9H694	—	0.990	Q9H694 →
KAT2A	Histone acetyltransferase KAT2A	0.990	landscape →
Q9WTU0	—	0.989	Q9WTU0 →
Q3UWM4	—	0.988	Q3UWM4 →
Q8K4S7	—	0.988	Q8K4S7 →
Q92833	—	0.987	Q92833 →
O88974	—	0.987	O88974 →
KDM7A	Lysine-specific demethylase 7A	0.987	landscape →
Q9HBD1	—	0.987	Q9HBD1 →
Q3UQU0	—	0.987	Q3UQU0 →
Q62925	—	0.987	Q62925 →
Q6P949	—	0.986	Q6P949 →
Q6GQL0	—	0.986	Q6GQL0 →
KAT2B	Histone acetyltransferase KAT2B	0.986	landscape →
Q5F363	—	0.986	Q5F363 →
Q08D35	—	0.986	Q08D35 →
Q64127	—	0.986	Q64127 →
Q498F0	—	0.986	Q498F0 →
Q8TEW8	—	0.986	Q8TEW8 →
O75916	—	0.986	O75916 →
E6ZGB4	—	0.985	E6ZGB4 →
Q68EF0	—	0.985	Q68EF0 →
A1L2G3	—	0.985	A1L2G3 →
O54828	—	0.985	O54828 →
Q63099	—	0.984	Q63099 →